Karvy Stock Broking Limited has maintained ‘Buy’ rating on State Bank Of India (SBI) stock to achieve a target of Rs 1350 within 1-2 days.

According to Karvy, day traders can buy the stock at Rs 1305 with a stop loss of Rs 1275.

Shares of the bank, on Monday (April 20), closed at Rs 1295.95 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 130.14 and 9.59 respectively. The share price has seen a 52-week high of Rs 1840 and a low of Rs 894 on BSE.

In its latest research report, Nirmal Bang, an equity research firm, has maintained ‘Buy’ rating on Kalindee Rail Nirman Engineers stock, which will give good returns within 4-5 trading session.

The report further stated that, if the counter is successful to breach 117, then it will create a huge breakout.

Nirmal Bang Research has advised its clients to hold the scrip with a target price of Rs 125-137.

In addition, the firm has suggested a support level for the scrip between Rs 91-92.

Nirmal Bang has maintained its ‘Buy’ rating on Kingfisher Airlines Limited to achieve a target of Rs 47.50 within 1-5 days.

Traders can buy the stock on dips with a stop loss of Rs 34.90.

Shares of the company, on Monday (April 20), closed at Rs 38.80 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 158.50 and a low of Rs 22 on BSE.

Air France-KLM is making discussions with Kingfisher and Jet Airways in order to serve up Indian secondary markets.

Nirmal Bang Research is bullish on Deccan Chronicle Holdings Ltd (DCHL) and maintained ‘Buy’ rating on the stock to achieve a target of Rs 69 within 1-5 days.

Traders can buy the stock on dips with a stop loss of Rs 52.

Shares of the company, on Monday (April 20), closed at Rs 59.80 on the Bombay Stock Exchange (BSE). Current EPS & P/E ratio stood at 5.50 and 11.27 respectively. The share price has seen a 52-week high of Rs 160 and a low of Rs 25.50 on BSE.

A recent scrutiny of drug-manufacturer Cipla's Bangalore plant by the US Food and Drug Administration (FDA) revealed as many as nine deviations in the pharma firm's manufacturing process.

With the reports about the digression found at the plant, the shares of Cipla suffered a blow at the Bombay Stock Exchange (BSE), as well as the National Stock Exchange (NSE), on Monday. Despite the company justifying its stand and terming the deviations as "minor ones" relating to manufacturing practices, the stock fell at the BSE.

With the Wall Street Journal reporting that some problems had occurred in Suzlon Energy Ltd's supply of blades to REpower Systems AG for a project in China, the shares of the company - India's foremost wind-turbine generators' manufacturer - plunged 19 percent to Rs 55.95 on the National Stock Exchange on Thursday.

While Suzlon's blades have reportedly been rejected, the company - which owns 74 percent of Germany's REpower and is looking at increasing its stake beyond 90 per cent - denied any problem, saying that prototypes were being tested and the actual delivery would begin in a couple of months.